Online inquiry

IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9567MR)

This product GTTS-WQ9567MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR&MET gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2; NM_000245.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956; 4233
UniProt ID Q504U8; P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9567MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14901MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ7737MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ7382MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ95MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ4169MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ6460MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ6745MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ3275MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW